# Obesity or Overweight FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/obesity-or-overweight

> 4 upcoming FDA catalysts in obesity or Overweight: maridebart cafraglutide (AMGN) on Jan to Apr 2028 (topline data readout); maridebart cafraglutide (AMGN) on January 2028 (primary completion); lenbelintide (AZN) on Aug to Nov 2028 (topline data readout); lenbelintide (AZN) on August 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 21, 2025 | [Active imp primary completion](https://sec-api.dev/pdufa/active-imp) | AZN | Obesity or Overweight | completed | "NCT06579092 (Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06579092)) |
| December 3, 2025 | [AZD6234 primary completion](https://sec-api.dev/pdufa/azd6234) | AZN | Obesity or Overweight | completed | "NCT06595238 (A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-03 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06595238)) |
| May 11, 2026 | [AZD9550 primary completion](https://sec-api.dev/pdufa/azd9550) | AZN | Obesity or Overweight | completed | "NCT06862791 (A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06862791)) |
| Jan to Apr 2028 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity or Overweight | scheduled | "NCT07575399 (Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-03 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575399)) |
| January 2028 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity or Overweight | scheduled | "NCT07575399 (Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-03 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575399)) |
| Aug to Nov 2028 | [Lenbelintide topline data readout](https://sec-api.dev/pdufa/lenbelintide) | AZN | Obesity or Overweight | scheduled | "NCT07784725 (A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07784725)) |
| August 2028 | [Lenbelintide primary completion](https://sec-api.dev/pdufa/lenbelintide) | AZN | Obesity or Overweight | scheduled | "NCT07784725 (A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07784725)) |

## Drugs

- [Active imp](https://sec-api.dev/pdufa/active-imp) (AZN)
- [AZD6234](https://sec-api.dev/pdufa/azd6234) (AZN)
- [AZD9550](https://sec-api.dev/pdufa/azd9550) (AZN)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)
- [Lenbelintide](https://sec-api.dev/pdufa/lenbelintide) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/obesity-or-overweight.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Obesity or Overweight FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/obesity-or-overweight

```bibtex
@misc{secapidev_indications_obesity_or_overweight_20261116,
  title        = {Obesity or Overweight FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/obesity-or-overweight}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_obesity_or_overweight_20261116","title":"Obesity or Overweight FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/obesity-or-overweight","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
